绝经后骨质疏松免疫防治新靶点:肠道菌群

A new target of immune treatment for postmenopausal osteoporosis: intestinal flora

随着社会人口老龄化问题逐渐严重,骨质疏松尤其是绝经后骨质疏松(PMO)愈发威胁着群众的生命健康安全。目前临床上抗骨质疏松的治疗主要为抑制骨吸收和促进骨形成的药物治疗,包括二膦酸盐类、降钙素、甲状旁腺素等,但药物的副作用及高昂经济成本一定程度上限制其使用范围。肠道被誉为人体的第二个大脑,肠道菌群是其中发挥功能的神经元,调节全身组织系统的协调运作,尤其是参与调控PMO。肠道菌群调节骨代谢机制的发现使肠道菌群治疗骨质疏松成为研究热点。本文综述肠道菌群调控PMO的最新研究进展,阐明肠道菌群调控PMO的相关作用机制,分析肠道菌群治疗PMO的研究现状及临床应用前景。

As the progress of population aging of society,osteoporosis especially postmenopausal osteoporosis(PMO)has increased dramatically and severely threatened the health of the public.Nowadays,the clinical commonly used treatments for osteoporosis include bisphosphonates,calcitonin and parathyroid hormone,which are working by inhibiting bone resorption and promoting bone formation.But the severe side effects and the expensive cost might limit their application in some extent.Intestinal tract is known as the second brain of human body.Intestinal flora is the functional neuron,which regulates the coordinated operation of the whole body tissue system,especially participates in the regulation of PMO.However,with the discovery of intestinal flora regulating bone metabolism,microbiological treatment for osteoporosis has become a research hotspot.This article reviewed the latest research progress of microbiological treatment for PMO,clarified the mechanisms of intestinal flora regulating PMO,and analyzed the current research status and clinical prospect of this treatment.